NASDAQ : GNPX
Genprex, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.84M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.02M | 6.09M | 9.83M | 13.43M | 12.30M | 11.68M |
| Research & Development | 9.82M | 9.43M | 10.54M | 17.62M | 11.51M | 8.97M |
| Operating Expenses | 15.84M | 15.52M | 20.37M | 31.06M | 23.83M | 20.67M |
| Operating Income | -15.84M | -15.52M | -20.37M | -31.06M | -23.83M | -20.67M |
| Interest Expense | -739.93K | -739.93K | ||||
| Interest & Investment Income | 26.90K | 26.90K | 63.57K | 215.11K | 90.10K | 5.13K |
| Other Non Operating Income (Expenses) | 57.18K | -299.00 | -570.00 | -18.68K | ||
| EBT Excluding Unusual Items | -16.50M | -16.23M | -20.31M | -30.86M | -23.74M | -20.66M |
| Other Unusual Items | -800.00K | |||||
| Pretax Income | -16.50M | -16.23M | -21.11M | -30.86M | -23.74M | -20.66M |
| Income Tax Expense | 2.65K | |||||
| Net Income | -16.50M | -16.23M | -21.11M | -30.86M | -23.74M | -20.66M |
| Preferred Dividends & Other Adjustments | 277.12K | |||||
| Net Income to Common | -16.50M | -16.23M | -21.39M | -30.86M | -23.74M | -20.66M |
| Shares Outstanding (Basic) | 230.14K | 42.40K | ||||
| Shares Outstanding (Diluted) | 230.14K | 42.40K | ||||
| EPS (Basic) | -71.69 | -382.79 | ||||
| EPS (Diluted) | -71.69 | -382.79 | ||||
| Free Cash Flow | -15.56M | -15.31M | -17.92M | -24.74M | -17.62M | -14.32M |
| Free Cash Flow Per Share | -67.62 | -361.14 | ||||
| EBITDA | -15.51M | -20.36M | -31.04M | -23.81M | -20.65M | |
| D&A For EBITDA | 6.69K | 6.69K | 15.00K | 25.57K | 22.53K | |
| EBIT | -15.84M | -15.52M | -20.37M | -31.06M | -23.83M | -20.67M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 15.15M | 7.83M | 1.60M | 6.74M | 20.95M | 38.63M |
| Cash & Short-Term Investments | 15.15M | 7.83M | 1.60M | 6.74M | 20.95M | 38.63M |
| Other Receivables | 34.85K | |||||
| Receivables | 34.85K | |||||
| Prepaid Expenses | 688.63K | 525.93K | 475.81K | 794.14K | 484.22K | 511.35K |
| Total Current Assets | 15.84M | 8.36M | 2.08M | 7.53M | 21.47M | 39.14M |
| Property, Plant & Equipment | 7.86K | 23.03K | 48.61K | |||
| Other Intangible Assets | 773.48K | 702.10K | 642.36K | |||
| Other Long-Term Assets | 1.29M | 1.80M | 2.05M | 2.36M | 2.89M | 3.03M |
| Total Assets | 17.14M | 10.16M | 4.12M | 10.67M | 25.09M | 42.86M |
| Accounts Payable | 293.58K | 743.07K | 1.07M | 1.40M | 442.93K | 973.20K |
| Other Current Liabilities | 2.05M | 1.43M | 1.43M | 1.86M | 2.37M | 612.10K |
| Total Current Liabilities | 2.34M | 2.17M | 2.50M | 3.25M | 2.81M | 1.59M |
| Other Long-Term Liabilities | 22.50K | |||||
| Total Liabilities | 2.34M | 2.20M | 2.50M | 3.25M | 2.81M | 1.59M |
| Common Stock | 506.00 | 3.29K | 217.00 | 1.49K | 1.20K | 47.87K |
| Additional Paid-In Capital | 194.73M | 178.99M | 156.42M | 141.10M | 125.10M | 120.32M |
| Retained Earnings | -179.94M | -171.03M | -154.80M | -133.69M | -102.83M | -79.09M |
| Total Common Equity | 14.80M | 7.96M | 1.62M | 7.42M | 22.27M | 41.28M |
| Shareholders' Equity | 14.80M | 7.96M | 1.62M | 7.42M | 22.27M | 41.28M |
| Total Liabilities & Equity | 17.14M | 10.16M | 4.12M | 10.67M | 25.09M | 42.86M |
| Net Cash (Debt) | 15.15M | 7.83M | 1.60M | 6.74M | 20.95M | 38.63M |
| Net Cash Per Share | 65.85 | 184.70 | ||||
| Filing Date Shares Outstanding | 819.71K | 411.13K | 21.96K | |||
| Total Common Shares Outstanding | 506.22K | 149.61K | ||||
| Working Capital | 13.50M | 6.18M | -426.70K | 4.28M | 18.66M | 37.55M |
| Book Value Per Share | 29.23 | 53.22 | ||||
| Tangible Book Value | 14.80M | 7.96M | 1.62M | 6.64M | 21.57M | 40.63M |
| Tangible Book Value Per Share | 29.23 | 53.22 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -16.50M | -16.23M | -21.11M | -30.86M | -23.74M | -20.66M |
| Depreciation & Amortization | 6.69K | 15.00K | 25.57K | 22.53K | ||
| Stock-Based Compensation | -185.08K | 312.83K | 3.30M | 5.41M | 4.73M | 5.35M |
| Other Operating Activities | 739.93K | 739.93K | ||||
| Change in Accounts Receivable | 34.85K | -34.85K | 127.00 | |||
| Change in Accounts Payable | -637.23K | -331.23K | -323.31K | 954.69K | -530.27K | 780.23K |
| Change in Other Net Operating Assets | 1.02M | 196.20K | 202.24K | -291.41K | 1.93M | 229.60K |
| Operating Cash Flow | -15.56M | -15.31M | -17.92M | -24.74M | -17.62M | -14.28M |
| Capital Expenditures | -31.70K | |||||
| Sale of Property, Plant & Equipment | 1.17K | 169.00 | ||||
| Sale (Purchase) of Intangibles | 773.48K | -71.38K | -59.73K | -52.10K | ||
| Investing Cash Flow | 774.64K | -71.21K | -59.73K | -83.80K | ||
| Issuance of Common Stock | 29.37M | 21.54M | 12.01M | 10.59M | 6.43K | 25.68M |
| Financing Cash Flow | 29.37M | 21.54M | 12.01M | 10.59M | 6.43K | 25.68M |
| Net Cash Flow | 13.81M | 6.23M | -5.14M | -14.22M | -17.67M | 11.31M |
| Free Cash Flow | -15.56M | -15.31M | -17.92M | -24.74M | -17.62M | -14.32M |
| Free Cash Flow Per Share | -67.62 | -361.14 | ||||
| Levered Free Cash Flow | -10.58M | -10.23M | -8.98M | -13.89M | -8.98M | -6.62M |
| Unlevered Free Cash Flow | -10.11M | -9.76M | -8.98M | -13.89M | -8.98M | -6.62M |
| Change in Working Capital | 381.00K | -135.03K | -121.08K | 698.13K | 1.36M | 1.01M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.84M | 4.06M | 7.24M | 13.66M | 69.61M | 62.60M |
| Enterprise Value | -13.32M | 2.95M | 5.76M | 1.95M | 44.09M | 20.58M |
| Last Close Price | 2.24 | 38.50 | 936.76 | 10,120.03 | 63,800.20 | 57,640.18 |
| Forward PE | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 | |
| PB Ratio | 0.08 | 0.51 | 4.47 | 1.84 | 3.12 | 1.52 |
| P/TBV Ratio | 0.12 | 0.51 | 4.47 | 2.06 | 3.23 | 1.54 |
| Net Debt / Equity Ratio | -1.02 | -0.98 | -0.99 | -0.91 | -0.94 | -0.94 |
| Net Debt / EBITDA Ratio | 0.51 | 0.08 | 0.22 | 0.88 | 1.87 | |
| Net Debt / FCF Ratio | 0.97 | 0.51 | 0.09 | 0.27 | 1.19 | 2.70 |
| Quick Ratio | 6.47 | 3.60 | 0.64 | 2.07 | 7.47 | 24.37 |
| Current Ratio | 6.76 | 3.84 | 0.83 | 2.31 | 7.64 | 24.69 |
| Return on Equity (ROE) | -203.86% | -338.74% | -467.24% | -207.88% | -74.71% | -57.25% |
| Return on Assets (ROA) | -94.46% | -135.78% | -172.12% | -108.57% | -43.84% | -34.81% |
| Return on Capital Employed (ROCE) | -107.10% | -194.30% | -1,257.40% | -418.80% | -107.00% | -50.10% |
| Earnings Yield | -3,200.47% | -399.92% | -291.39% | -225.88% | -34.11% | -33.01% |
| FCF Yield | -847.57% | -377.30% | -247.38% | -181.08% | -25.32% | -22.87% |